Reckitt vs Roche

Veet, Gocomo Launch 'The Smooth Switch' Creator Campaign

Veet has launched a summer creator campaign called "The Smooth Switch" in collaboration with Berlin-based social-first agency Gocomo. The campaign addresses hair removal with a humorous and deliberately imperfect tone and aims to generate buzz through the participation of eight creators. The article notes this is the first direct collaboration between the brand and the agency and references Gocomo's work with other Reckitt-owned brands such as Durex.

• Veet launched a summer creator campaign named "The Smooth Switch".
• The campaign was developed with Berlin social-first agency Gocomo.
• The campaign adopts a humorous, intentionally imperfect approach to hair removal.

Emerging Markets Boost Reckitt Half-Year Results

Reckitt, the British consumer goods company, said demand for cleaning and hygiene products in markets such as China and India strengthened its business in the first half of the year (period ending 30 June 2026). The company confirmed its full-year guidance and announced a share buyback, according to the publisher's report based on Reckitt's half-year results. The article was published by Lebensmittelzeitung on 2026-07-29.

• Reckitt reported stronger business in the first six months of 2026 driven by demand in emerging markets including China and India.
• The reporting period referenced is the first half of the year ending 30 June 2026.
• Reckitt confirmed its existing forecast (guidance) for the year.

Zenith Retains Reckitt’s $400M U.S. Media Account

Publicis Media agency Zenith has retained Reckitt’s U.S. media business after a competitive pitch that concluded with a head-to-head against WPP Media. The U.S. account is reported at $400 million. Separately, WPP won Reckitt’s European media business in November 2025, managing media across 21 markets in an account estimated at $700 million by COMvergence. Zenith had been the incumbent in the U.K. as Reckitt moved to simplify its global media structure, according to Reckitt executives.

• Zenith (a Publicis Media agency) retained Reckitt’s U.S. media business in a competitive pitch.
• The U.S. media account is reported at $400 million.
• WPP won Reckitt’s European media business in November 2025, managing media across 21 markets—an account estimated at $700 million by COMvergence.

Roche and Ypsomed Stay Top in Swiss Reputation Ranking

Swissreputation Group and Pressrelations Schweiz analyzed nearly 90,000 reputation-relevant statements from about 4,000 Swiss online and print sources using an AI-supported method to evaluate media reputation for 40 pharma and medtech companies. The study measured presence (coverage and reach) and tonality (positive/negative reporting) and calculated a Reputation Score (0–100) for each company across six reputation dimensions. In Pharma & Biopharma, Roche ranks first (ahead of MSD, Novartis, Sandoz and AstraZeneca). In MedTech & Diagnostics, Ypsomed remains first (ahead of Medacta, Straumann Group, Alcon and Sonova). The study notes products/services, innovation and economic performance tended to improve media reputation, while workplace issues (layoffs, relocations) and ESG/legal problems harmed reputation. The article was published on 2026-08-13.

• Swissreputation Group and Pressrelations Schweiz analyzed nearly 90,000 reputation-relevant statements from about 4,000 Swiss online and print sources using an AI-supported method.
• The study measured presence and tonality for 40 pharma and medtech companies and computed a Reputation Score between 0 and 100 across six reputation dimensions.
• In the Pharma & Biopharma category, Roche ranked first, followed by MSD, Novartis, Sandoz and AstraZeneca.

Roche Pharma Day 2026 announced

Roche Pharma Day 2026 will be held on Monday, 28th September 2026, 09:00am BST. More details available via the investor update.

Investor Presentation Released: Roche

AI parsed presentation narrative: Roche is successfully transitioning to a post-pandemic growth phase, with base business growth of 7% and core operating profit expanding faster than sales. The strategy focuses on maximizing high-growth franchises like Vabysmo and Ocrevus while aggressively expanding into the obesity market and AI-driven diagnostics. Strategic pillars: Maximizing value of existing growth drivers, Leading in Obesity and Metabolic disease.